ChiCTR2500114454 版本V1.0 版本创建时间2025/12/12 08:51:37 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500114454 

最近更新日期:

Date of Last Refreshed on:

2025-12-12 08:51:24 

注册时间:

Date of Registration:

2025-12-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

气管镜下介入治疗对结核病合并气道狭窄的远期疗效与安全性分析——一项全国多中心临床队列研究

Public title:

Long-term Efficacy and Safety of Bronchoscopic Interventional Therapy for Tuberculosis-related Airway Stenosis: A Nationwide Multicenter Clinical Cohort Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

气管镜下介入治疗对结核病合并气道狭窄的远期疗效与安全性分析——一项全国多中心临床队列研究

Scientific title:

Long-term Efficacy and Safety of Bronchoscopic Interventional Therapy for Tuberculosis-related Airway Stenosis: A Nationwide Multicenter Clinical Cohort Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

聂文娟 

研究负责人:

聂文娟 

Applicant:

Nie Wenjuan 

Study leader:

Nie Wenjuan 

申请注册联系人电话:

Applicant telephone:

+86 135 5215 6672

研究负责人电话:

Study leader's
telephone:

+86 135 5215 6672

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

94642975@qq.com

研究负责人电子邮件:

Study leader's E-mail:

94642975@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市通州区北关大街9号院一区

研究负责人通讯地址:

北京市通州区北关大街9号院一区

Applicant address:

No. 9 Courtyard 1, Beiguan Avenue, Tongzhou District, Beijing

Study leader's address:

No. 9 Courtyard 1, Beiguan Avenue, Tongzhou District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京胸科医院

Applicant's institution:

Beijing Chest Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京胸科医院

Affiliation of the Leader:

Beijing Chest Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LW-2025-035

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京胸科医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing Chest Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-25 00:00:00

伦理委员会联系人:

张彤群

Contact Name of the ethic committee:

Zhang Tongqun

伦理委员会联系地址:

北京市通州区北关大街9号院一区

Contact Address of the ethic committee:

No. 9 Courtyard 1, Beiguan Avenue, Tongzhou District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8950 9134

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京胸科医院

Primary sponsor:

Beijing Chest Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市通州区北关大街9号院一区

Primary sponsor's address:

No. 9 Courtyard 1, Beiguan Avenue, Tongzhou District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京胸科医院

具体地址:

北京市通州区北关大街9号院一区

Institution
hospital:

Beijing Chest Hospital, Capital Medical University

Address:

No. 9 Courtyard 1, Beiguan Avenue, Tongzhou District, Beijing

经费或物资来源:

天津市医学重点学科建设(TJYXZDXK-3-018B)

Source(s) of funding:

Tianjin Key Medical Discipline Construction Program (TJYXZDXK-3-018B)

研究疾病:

气管支气管结核  

Target disease:

tracheobronchial tuberculosis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

通过对比球囊扩张术、支架置入术与非手术治疗三种方案的疗效与安全性,旨在为临床决策提供循证依据。  

Objectives of Study:

By comparing the efficacy and safety of balloon dilation, stent placement, and non-surgical management, this study aims to provide evidence-based guidance for clinical decision-making.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经临床诊断为结核病合并气道狭窄; 2.接受非手术治疗、支架置入治疗或球囊扩张治疗; 3.有完整的临床资料和随访记录。

Inclusion criteria

1. Clinically diagnosed with tuberculosis complicated by airway stenosis; 2. Underwent non-surgical treatment, stent placement, or balloon dilation; 3. Possess complete clinical data and follow-up records.

排除标准:

1.合并其他严重呼吸系统疾病; 2.治疗过程中出现严重并发症,影响疗效判断; 3.随访资料不完整。

Exclusion criteria:

1. Presence of other serious respiratory diseases; 2. Serious complications occur during treatment, affecting the assessment of efficacy; 3. Incomplete follow-up data.

研究实施时间:

Study execute time:

From 2025-12-20 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-20 00:00:00 To 2025-12-26 00:00:00

干预措施:

Interventions:

组别:

非手术组

样本量:

57

Group:

Non-surgical group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

支架置入术组

样本量:

31

Group:

Stent placement group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

球囊扩张术组

样本量:

26

Group:

Balloon dilation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京胸科医院 

单位级别:

三甲 

Institution
hospital:

Beijing Chest Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市海河医院 

单位级别:

三甲 

Institution
hospital:

Tianjin Haihe Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

症状好转率

指标类型:

主要指标

Outcome:

Symptom improvement rate

Type:

Primary indicator

测量时间点:

在接受气管镜下治疗后1年

测量方法:

Measure time point of outcome:

One year after undergoing bronchoscopic intervention

Measure method:

指标中文名:

症状无变化率

指标类型:

次要指标

Outcome:

rate of unchanged symptoms

Type:

Secondary indicator

测量时间点:

在接受气管镜下治疗后1年

测量方法:

Measure time point of outcome:

One year after undergoing bronchoscopic intervention

Measure method:

指标中文名:

症状加重率

指标类型:

次要指标

Outcome:

rate of worsened symptoms

Type:

Secondary indicator

测量时间点:

在接受气管镜下治疗后1年

测量方法:

Measure time point of outcome:

One year after undergoing bronchoscopic intervention

Measure method:

指标中文名:

全因死亡率

指标类型:

次要指标

Outcome:

all-cause mortality rate

Type:

Secondary indicator

测量时间点:

在接受气管镜下治疗后1年

测量方法:

Measure time point of outcome:

One year after undergoing bronchoscopic intervention

Measure method:

指标中文名:

负面结局率

指标类型:

次要指标

Outcome:

rate of composite negative outcome

Type:

Secondary indicator

测量时间点:

在接受气管镜下治疗后1年

测量方法:

Measure time point of outcome:

One year after undergoing bronchoscopic intervention

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理采用EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management were conducted using EDC.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-12 08:51:24